{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:31:57Z","timestamp":1760488317773,"version":"build-2065373602"},"reference-count":33,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2025.2894","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:41:11Z","timestamp":1757500871000},"page":"1-5","source":"Crossref","is-referenced-by-count":1,"title":["Drug\u2011induced interstitial lung disease caused by gefitinib in the treatment of non\u2011small cell lung cancer: A case report"],"prefix":"10.3892","volume":"23","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[{"name":"Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuping","family":"Sun","sequence":"additional","affiliation":[{"name":"Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong 250117, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"key20251014162141_b1-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.jtho.2019.06.011","article-title":"Prevention and early detection for NSCLC: Advances in thoracic oncology 2018","volume":"14","author":"Balata","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"71","key":"key20251014162141_b2-MCO-23-5-02894","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"e2307360","key":"key20251014162141_b3-MCO-23-5-02894","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202307360","article-title":"AuNPs\/CNC nanocomposite with A \u2018Dual Dispersion\u2019 Effect for LDI-TOF MS analysis of intact proteins in NSCLC serum exosomes","volume":"11","author":"Shan","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"key20251014162141_b4-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"key20251014162141_b5-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S2213-2600(25)00121-3","article-title":"Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: A randomised, double-blind, double-dummy, phase 3 trial","volume":"13","author":"Shi","year":"2025","journal-title":"Lancet Respir Med"},{"key":"key20251014162141_b6-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/ajco.13234","article-title":"Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancer","volume":"15","author":"Gibson","year":"2019","journal-title":"Asia Pac J Clin Oncol"},{"key":"key20251014162141_b7-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s11864-024-01257-6","article-title":"Management of pulmonary toxicities associated with systemic therapy in non-small cell lung cancer","volume":"25","author":"Velimirovic","year":"2024","journal-title":"Curr Treat Options Oncol"},{"issue":"100404","key":"key20251014162141_b8-MCO-23-5-02894","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: Expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"key20251014162141_b9-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JTO.0b013e3181ca12e0","article-title":"Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: The Okayama lung cancer study group experience","volume":"5","author":"Hotta","year":"2010","journal-title":"J Thorac Oncol"},{"key":"key20251014162141_b10-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"key20251014162141_b11-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4143\/crt.2014.201","article-title":"Gefitinib-induced interstitial lung disease in Korean lung cancer patients","volume":"48","author":"Beom","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"39","key":"key20251014162141_b12-MCO-23-5-02894","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-13-39","article-title":"Drug-induced interstitial lung disease: Mechanisms and best diagnostic approaches","volume":"13","author":"Matsuno","year":"2012","journal-title":"Respir Res"},{"issue":"792","key":"key20251014162141_b13-MCO-23-5-02894","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020792","article-title":"Molecular and clinical features of EGFR-TKI-associated lung injury","volume":"22","author":"Ohmori","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20251014162141_b14-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1088\/0031-9155\/56\/4\/016","article-title":"Computer-aided detection of early interstitial lung diseases using low-dose CT images","volume":"56","author":"Park","year":"2011","journal-title":"Phys Med Biol"},{"key":"key20251014162141_b15-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/ajco.13903","article-title":"Incidence and appropriate management of drug-induced interstitial lung disease in Japanese patients with unresectable pancreatic cancer: A multicenter retrospective study","volume":"19","author":"Miyagahara","year":"2023","journal-title":"Asia Pac J Clin Oncol"},{"issue":"336","key":"key20251014162141_b16-MCO-23-5-02894","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030366","article-title":"Newer-generation EGFR inhibitors in lung cancer: How are they best used?","volume":"11","author":"Le","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20251014162141_b17-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-019-03788-4","article-title":"Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer","volume":"83","author":"Kawata","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20251014162141_b18-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1177\/03008916211047888","article-title":"Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"108","author":"Taronna","year":"2022","journal-title":"Tumori"},{"key":"key20251014162141_b19-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1111\/cas.12550","article-title":"Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10708 Japanese patients with non-small-cell lung cancer","volume":"105","author":"Gemma","year":"2014","journal-title":"Cancer Sci"},{"issue":"111067","key":"key20251014162141_b20-MCO-23-5-02894","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.111067","article-title":"The role of heat shock proteins in the regulation of fibrotic diseases","volume":"135","author":"Zhang","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"e27296","key":"key20251014162141_b21-MCO-23-5-02894","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027296","article-title":"Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis","volume":"6","author":"Namba","year":"2011","journal-title":"PLoS One"},{"issue":"9316","key":"key20251014162141_b22-MCO-23-5-02894","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179316","article-title":"Extracellular heat shock proteins as therapeutic targets and biomarkers in fibrosing interstitial lung diseases","volume":"22","author":"Tanguy","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20251014162141_b23-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"550","DOI":"10.18632\/oncotarget.939","article-title":"Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia","volume":"4","author":"Ishiguro","year":"2013","journal-title":"Oncotarget"},{"key":"key20251014162141_b24-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2014.07.021","article-title":"High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer","volume":"86","author":"Fujita","year":"2014","journal-title":"Lung Cancer"},{"key":"key20251014162141_b25-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/jjco\/hyt049","article-title":"Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: Combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405)","volume":"43","author":"Akamatsu","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"key20251014162141_b26-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40261-024-01400-z","article-title":"Diagnosis and management of drug-induced interstitial lung disease in the context of anti-cancer therapy: A multidisciplinary viewpoint by portuguese experts","volume":"44","author":"Fontes","year":"2024","journal-title":"Clin Drug Investig"},{"key":"key20251014162141_b27-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s12032-010-9424-4","article-title":"Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: A case report and literature review","volume":"28","author":"Kuo","year":"2011","journal-title":"Med Oncol"},{"key":"key20251014162141_b28-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.21037\/jtd-2025-292","article-title":"Expert consensus on cancer treatment-related lung injury","volume":"17","author":"Lin","year":"2025","journal-title":"J Thorac Dis"},{"key":"key20251014162141_b29-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.3892\/ol.2015.3026","article-title":"Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature","volume":"9","author":"Zhang","year":"2015","journal-title":"Oncol Lett"},{"key":"key20251014162141_b30-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11523-024-01048-x","article-title":"Real-world data on subsequent therapy for first-line osimertinib-induced pneumonitis: Safety of EGFR-TKI rechallenge (Osi-risk Study TORG-TG2101)","volume":"19","author":"Nishioka","year":"2024","journal-title":"Target Oncol"},{"key":"key20251014162141_b31-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2169\/internalmedicine.8947-17","article-title":"Successful osimertinib rechallenge with steroid therapy after osimertinib-induced interstitial lung disease","volume":"57","author":"Kiriu","year":"2018","journal-title":"Intern Med"},{"key":"key20251014162141_b32-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1002\/cam4.4750","article-title":"Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib","volume":"11","author":"Shibaki","year":"2022","journal-title":"Cancer Med"},{"key":"key20251014162141_b33-MCO-23-5-02894","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.lungcan.2006.02.002","article-title":"Imaging of gefitinib-related interstitial lung disease: Multi-institutional analysis by the West Japan thoracic oncology group","volume":"52","author":"Endo","year":"2006","journal-title":"Lung Cancer"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:22:13Z","timestamp":1760448133000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2025.2894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":33,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9,10]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2025.2894","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"type":"print","value":"2049-9450"},{"type":"electronic","value":"2049-9469"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}